Helius Medical Tech Analyst Ratings
Helius Medical Tech Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2022 | 809.09% | Roth Capital | → $5 | Initiates Coverage On | → Buy |
| 11/15/2021 | — | Noble Capital Markets | Downgrades | Outperform → Market Perform | |
| 03/24/2021 | 3536.36% | Noble Capital Markets | → $20 | Initiates Coverage On | → Outperform |
| 04/16/2019 | — | BTIG | Downgrades | Buy → Neutral | |
| 04/11/2019 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 03/06/2019 | — | Oppenheimer | Initiates Coverage On | → Outperform | |
| 11/20/2018 | 2445.45% | BTIG | → $14 | Upgrades | Neutral → Buy |
| 06/19/2018 | — | BTIG | Downgrades | Buy → Neutral | |
| 05/17/2018 | 2445.45% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 8 月 23 日 | 809.09% | 罗斯资本 | → 5 美元 | 启动覆盖范围开启 | → 购买 |
| 11/15/2021 | — | 贵族资本市场 | 降级 | 跑赢大盘 → 市场表现 | |
| 2021 年 3 月 24 日 | 3536.36% | 贵族资本市场 | → 20 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 04/16/2019 | — | BTIG | 降级 | 买入 → 中性 | |
| 04/11/2019 | — | 奥本海默 | 降级 | 跑赢大盘 → 表现 | |
| 03/06/2019 | — | 奥本海默 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 11/20/2018 | 2445.45% | BTIG | → 14 美元 | 升级 | 中性 → 买入 |
| 06/19/2018 | — | BTIG | 降级 | 买入 → 中性 | |
| 05/17/2018 | 2445.45% | BTIG | → 14 美元 | 启动覆盖范围开启 | → 购买 |
Helius Medical Tech Questions & Answers
Helius 医疗技术问题与解答
The latest price target for Helius Medical Tech (NASDAQ: HSDT) was reported by Roth Capital on August 23, 2022. The analyst firm set a price target for $5.00 expecting HSDT to rise to within 12 months (a possible 809.09% upside). 2 analyst firms have reported ratings in the last year.
罗斯资本于2022年8月23日公布了Helius Medical Tech（纳斯达克股票代码：HSDT）的最新目标股价。该分析公司将目标股价定为5.00美元，预计HSDT将在12个月内升至12个月内（可能上涨809.09％）。去年有两家分析公司公布了评级。
The latest analyst rating for Helius Medical Tech (NASDAQ: HSDT) was provided by Roth Capital, and Helius Medical Tech initiated their buy rating.
罗斯资本对Helius Medical Tech（纳斯达克股票代码：HSDT）的最新分析师评级由罗斯资本提供，Helius Medical Tech启动了买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Helius Medical Tech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Helius Medical Tech was filed on August 23, 2022 so you should expect the next rating to be made available sometime around August 23, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Helius Medical Tech的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Helius Medical Tech的最新评级是在2022年8月23日发布的，因此您应该预计下一个评级将在2023年8月23日左右公布。
While ratings are subjective and will change, the latest Helius Medical Tech (HSDT) rating was a initiated with a price target of $0.00 to $5.00. The current price Helius Medical Tech (HSDT) is trading at is $0.55, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Helius Medical Tech（HSDT）评级是启动的，目标股价为0.00美元至5.00美元。Helius Medical Tech（HSDT）目前的交易价格为0.55美元，在分析师的预测区间内。